Top

Published in:

01-02-2011 | Original Article

Anti-ribonucleoproteins autoantibodies in patients with systemic autoimmune diseases. Relation with cutaneous photosensitivity

Authors: Mariela L. Paz, Daniel H. González Maglio, María Pino, Alejandro Ferrari, Federico S. Weill, Gustavo Nasswetter, Juliana Leoni

Published in: Clinical Rheumatology | Issue 2/2011

Abstract

A common feature between patients with a certain group of systemic autoimmune pathologies (SAPs) with rheumatic component, such as lupus erythematosus (LE) in all its forms, is the presence of cutaneous photosensitivity (CP) as well as the existence of autoantibodies (Aabs). These Aabs have also high incidence in other SAPs that do not present CP, like primary Sjögren's syndrome and rheumatoid arthritis. Cutaneous photosensitivity is a condition that consists of an exacerbated skin reaction to solar radiations; its incidence can reach 90% in systemic LE. The mechanisms involved in the development of CP have been extensively studied focusing on different approaches; however, the exact mechanism has not been fully elucidated yet. There are many theories that relate specifically the presence of circulating anti-Ro/SS-A Aabs with the CP phenomenon, though there are several studies which are in disagreement. In this study, we evaluated the Aabs profile (anti-Ro/SS-A 52 kDa, anti-Ro/SS-A 60 kDa, anti-La/SS-B, anti-Sm and ANAs) as well as their titer or reactivity, in a local cohort of 169 patients with SAPs. We related those Aabs profiles and titers with the presence or absence of CP, and we found that there was no significant association between the presence of anti-Ro/SS-A Aabs and the occurrence of CP. On the other hand, a statistically significant positive association was found between CP and high reactivity anti-Sm Aabs, though this fact could be biased by the incidence of both events in SLE patients. To sum up, in the particular population studied, there is no direct relationship between anti-Ro/SS-A Aabs and CP, which is in agreement with some authors and in disagreement with many others, contributing to the endless discussion of this issue.

Scheinfeld N, Deleo VA (2004) Photosensitivity in lupus erythematosus. Photodermatol Photoimmunol Photomed 20:272–279CrossRefPubMed

Furukawa F, Hiroi A (2000) Collagen diseases in children. Clin Dermatol 18:725–733CrossRefPubMed

Von Muhlen CA, Tan EM (1995) Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum 24:323–358CrossRef

Schneeberger E, Citera G, Heredia M, Maldonado Cocco J (2008) Clinical significance of anti-Ro antibodies in rheumatoid arthritis. Clin Rheumatol 27:517–519CrossRefPubMed

Pan HF, Ye DO, Wang Q, Li WX, Zhang N, Li XP, Xu JH, Dai H (2008) Clinical and laboratory profiles of systemic lupus erythematosus associated with Sjögren syndrome in China: a study of 542 patients. Clin Rheumatol 27:339–343CrossRefPubMed

Fabini G, Rutjes SA, Zimmermann C, Pruijn GJM, Steiner G (2000) Analysis of the molecular composition of Ro ribonucleoprotein complexes. Identification of novel Y RNA-binding proteins. Eur J Biochem 267:2778–2789CrossRefPubMed

Reichlin M, Scofield RH (1996) SS-A (Ro) autoantibodies. In: Peter JP, Shoenfeld Y (eds) Autoantibodies. Elsevier, Amsterdam, The Netherlands, pp 783–788CrossRef

Herrmann M, Voll RE, Kalden JR (2000) Etiopathogenesis of systemic lupus erytematosus. Immunol Today 21:424–426CrossRefPubMed

Sonesson SE, Salomonsson S, Jacobson LA, Bremme K, Wahren-Herlenius M (2004) Signs of first degree heart block occurs in one third of fetuses of pregnant women with anti-SSA/Ro52 antibodies. Arthritis Rheum 50:1253–1261CrossRefPubMed

10.

Rutjes SA, Vree Egberts WTM, Jongen P, Van Den Hoogen F, Pruijn GJM, Van Venrooij WJ (1997) Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy. Clin Exp Immunol 109:32–40CrossRefPubMed

11.

Yoshimasu T, Hiroi A, Ohtani T, Uede K, Furukawa F (2002) Comparison of anti 60 and 52 kDa SS-A/Ro antibodies in the pathogenesis of cutaneous lupus erythematosus. Dermatol Sci 29(1):35–41CrossRef

12.

Tsuzaka K, Fujii T, Akizuki M, Mimori T, Tojo T, Fujii H, Tsukatani Y, Kubo A, Homma M (1994) Clinical significance of antibodies to native or denatured 60-kd or 52-kd Ro/SS-A proteins in Sjögren's syndrome. Arthritis Rheum 37(1):88–92CrossRefPubMed

13.

Morrison W (2004) Photosensitivity. N Engl J Med 350:1111–1117CrossRef

14.

Rhodes LE, Belgi G, Parslew R, McLoughlin L, Clough GF, Friedmann PS (2001) Ultraviolet-B-induced erythema is mediated by nitric oxide and prostaglandin E₂ in combination. J Invest Dermatol 117:880–885CrossRefPubMed

15.

Armstrong BK, Kricker A (2001) The epidemiology of UV induced skin cancer. J Photochem Photobiol B 63:8–18CrossRefPubMed

16.

Wysenbeek AJ, Block DA, Fries JF (1989) Prevalence and expression of photosensitivity in systemic lupus erythematosus. Ann Rheum Dis 48:461–463CrossRefPubMed

17.

Matsumara Y, Ananthaswamy HN (2004) The effects of ultraviolet radiation on the skin. Toxicol Appl Pharmacol 195:298–308CrossRef

18.

Paz ML, Gonzalez Maglio DH, Weill FS, Bustamante J, Leoni J (2008) Mitochondrial dysfunction and cellular stress progression after ultraviolet B irradiation in human keratinocytes. Photodermatol Photoimmunol Photomed 24(3):115–122CrossRefPubMed

19.

Caricchio R, McPhie L, Cohen PL (2003) Ultraviolet B radiation-induced cell death: critical role of ultraviolet dose in inflammation and lupus autoantigen redistribution. J Immunol 171(11):5778–5786PubMed

20.

Casciola-Rosen LA, Anhalt G, Rosen A (1994) Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 179:1317–1330CrossRefPubMed

21.

Ayukawa K, Taniguchi S, Masumoto J, Hashimoto S, Sarvathom H, Hara A, Aoyama T, Sagara J (2000) La autoantigen is cleaved in the COOH terminus and loses the nuclear localization signal during apoptosis. J Biol Chem 275(44):34465–34470CrossRefPubMed

22.

Mevorach D, Zhou JL, Song X, Elkon KB (1998) Systemic exposure to irradiated apoptotic cells induces autoantibody production. J Exp Med 188(2):387–392CrossRefPubMed

23.

Jones SK (1992) Ultraviolet radiation (UVR) induced cell surface Ro/SS-A antigen expression by human keratinocytes in vitro: a possible mechanism for the UVR induction of Cutaneous Lupus. Br J Dermatol 126:546–553CrossRefPubMed

24.

Furukawa F, Itoh T, Wakita H, Yagi H, Tokura Y, Norris DA, Takigawa M (1999) Keratinocytes from patients with lupus erythematosus show enhanced cytotoxicity to ultraviolet radiation and to antibody-mediated cytotoxicity. Clin Exp Immunol 118:164–170CrossRefPubMed

25.

Furukawa F (2003) Photosensitivity in cutaneous lupus erythematosus: lessons from mice and men. J Dermatol Sci 33:81–89CrossRefPubMed

26.

Furukawa F (1999) Antinuclear antibody-keratinocyte interactions in photosensitive cutaneous lupus erythematosus. Histol Histopathol 14(2):627–633PubMed

27.

Lee LA, Gaither KK, Coulter SN, Norris DA, Harley JB (1989) The pattern of cutaneous IgG deposition in cases of subacute cutaneous lupus erythematosus is reproduced by infusing purified anti-Ro (SSA) antibodies into human skin grafted mice. J Clin Invest 83:1556–1562CrossRefPubMed

28.

Ioannides D, Golden BD, Buyon JP (2000) Expression of SS-A/Ro and SS-B/La antigens in skin biopsy specimens of patients with photosensitivity forms of lupus erythematosus. Arch Dermatol 136(3):340–346CrossRefPubMed

29.

Furukawa F, Kanauchi H, Imamura S (1994) Susceptibility to UVB light in cultured keratinocytes of cutaneous lupus erythematosus. Dermatology 189(1):18–23CrossRefPubMed

30.

Furukawa F, Kashihara-Sawami M, Lyons MB, Norris DA (1990) Binding of antibodies to the extractable nuclear antigens SS-A/Ro and SS-B/La is induced on the surface of human keratinocytes by ultraviolet light (UVL): implications for the pathogenesis of photosensitivity cutaneous lupus. J Invest Dermatol 94(1):77–85CrossRefPubMed

31.

Golan TD, Elkon KB, Gharavi AE, Krueger JG (1992) Enhanced membrane binding of autoantibodies to cultured keratinocytes of systemic lupus erythematosus patients after ultraviolet B/ultraviolet A irradiation. J Clin Invest 90:1067–1076CrossRefPubMed

32.

Sutej PJ, Gear AJ, Morrison RCA, Tikly M, De Beer M, Dos Santos L, Sher R (1989) Photosensitivity and anti-Ro (SS-A) antibodies in black patients with systemic lupus erythematosus. Br J Rheumatol 28(4):321–324CrossRefPubMed

33.

Sanders CJ, Van Weelden H, Kazzaz GA, Sigurdsson V, Toonstra J, Bruijnzeel-Koomen CA (2003) Photosensitivity in patients with lupus erythematosus: a clinical and photobiological study of 100 patients using prolonged phototest protocol. Br J Dermatol 149:131–137CrossRefPubMed

34.

Yamamoto K (2003) Pathogenesis of Sjögren's syndrome. Autoimmun Rev 2(1):13–18CrossRefPubMed

35.

Nardi N, Brito-Zerón P, Ramos-Casals M, Aguiló S, Cervera R, Ingelmo M, Font J (2006) Circulating auto-antibodies against nuclear and non-nuclear antigens in primary Sjögren's syndrome. Prevalence and clinical significance in 335 patients. Clin Rheumatol 25:341–346CrossRefPubMed

36.

Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725CrossRefPubMed

37.

Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH, European Study Group on Classification Criteria for Sjögren's Syndrome (2002) Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61:554–558CrossRefPubMed

38.

Arnett FC, Edworthy SM, Bloch DA, Mcshane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA Jr, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG (1987) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324CrossRef

39.

Sambrook J, Russell DW (2001) Plasmids and their usefulness in molecular cloning. In: Molecular cloning: a laboratory manual, 3rd edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, New York. Vol 1, Chap 1, pp 1.116–1.118

40.

Hayek B, Vangelista L, Pastore A, Sperr WR, Valent P, Vrtala S, Niederberger V, Twardosz A, Kraft D, Valenta R (1998) Molecular and immunologic characterization of a highly cross-reactive two EF-hand calcium-binding alder pollen allergen, Aln g 4: structural basis for calcium-modulated IgE recognition. J Immunol 161:7031–7039PubMed

41.

Baer RL, Harber LC (1965) Photobiology of lupus erythematosus. Arch Dermatol 92:124–128CrossRef

42.

Everett MA, Olson RL (1965) Response of cutaneous lupus erythematosus to ultraviolet light. J Invest Dermatol 44:133–138PubMed

43.

Epstein JH, Tufanelli D, Dubois EL (1965) Light sensitivity and lupus erythematosus. Arch Dermatol 91:483–485CrossRefPubMed

44.

Furukawa F, Muto M (2009) Ethnic differences in immunogenetic features and photosensitivity of cutaneous lupus erythematosus. Arch Dermatol Res 301(1):111–115CrossRefPubMed

45.

Oke V, Vassilaki I, Espinosa A, Strandberg L, Kuchroo VK, Nyberg F, Wahren-Herlenius M (2009) High Ro52 expression in spontaneous and UV-induced cutaneous inflammation. J Invest Dermatol 129:2000–2010CrossRefPubMed

Title: Anti-ribonucleoproteins autoantibodies in patients with systemic autoimmune diseases. Relation with cutaneous photosensitivity
Authors: Mariela L. Paz
Daniel H. González Maglio
María Pino
Alejandro Ferrari
Federico S. Weill
Gustavo Nasswetter
Juliana Leoni
Publication date: 01-02-2011
Publisher: Springer-Verlag
Published in: Clinical Rheumatology / Issue 2/2011
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-010-1481-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2011

Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis

Interleukin-6 gene polymorphism in Iranian patients with systemic lupus erythematosus

Infrapatellar bursitis in children with juvenile idiopathic arthritis: a case series

Early onset systemic lupus erythematosus: differential diagnoses, clinical presentation, and treatment options

Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis

Adaptation of Turkish version of the questionnaire Quick Disability of the Arm, Shoulder, and Hand (Quick DASH) in patients with carpal tunnel syndrome

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials